Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651795 | 0.87 | KCNH2 (0.40) | KCNH2GRM5PTGS2LTA4HGRM2 | |
| SCHEMBL5653700 | 0.82 | KCNH2 (0.37) | KCNH2GRM5PTGS2LTA4H | |
| SCHEMBL1347174 | 0.75 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL14540425 | 0.74 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL509344 | 0.69 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL2716851 | 0.66 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL14599402 | 0.66 | KCNH2 (0.49) | KCNH2 | |
| Lersivirine SCHEMBL508446 | 0.66 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL5224343 | 0.66 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL10254059 | 0.66 | KCNH2 (0.44) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230025-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230025-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1546132-A1 | PYRAZOLE DERIVATIVES AS REVERSE TRANSCRIPTASE INHIBITORS | Pfizer Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20040110816-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004029042-A1 | PYRAZOLE DERIVATIVES AS REVERSE TRANSCRIPTASE INHIBITORS | PFIZER LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110816-A1 | Pyrazole derivatives | REV1, POLR2E, SARS1 | KCNH2 2890/4885GRM5 2749/4885PTGS2 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.